US FDA Device Center Hopes For ‘Normal Operations’ In 2022

 
• By Elizabeth Orr

Some device center functions should be back to user-fee timelines next year, but delays will persist in the divisions hardest hit by COVID-19, a blog post by top agency officials says.

FDA's Jeff Shuren (left) and William Maisel (right) said the agency greenlit a record number of novel devices in 2020.
FDA's Jeff Shuren (left) and William Maisel (right) discussed the device center's goals for getting back to pre-pandemic operations in 2022. • Source: US FDA

More from Regulation

More from Policy & Regulation